nomifensine has been researched along with Disorders of Excessive Somnolence in 1 studies
Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266)
nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.
Disorders of Excessive Somnolence: Disorders characterized by hypersomnolence during normal waking hours that may impair cognitive functioning. Subtypes include primary hypersomnia disorders (e.g., IDIOPATHIC HYPERSOMNOLENCE; NARCOLEPSY; and KLEINE-LEVIN SYNDROME) and secondary hypersomnia disorders where excessive somnolence can be attributed to a known cause (e.g., drug affect, MENTAL DISORDERS, and SLEEP APNEA SYNDROME). (From J Neurol Sci 1998 Jan 8;153(2):192-202; Thorpy, Principles and Practice of Sleep Medicine, 2nd ed, p320)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Animals were habituated overnight and dosed the next day, 5 h after lights on, with test agents." | 1.35 | The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents. ( Bozyczko-Coyne, D; Gasior, M; Gruner, JA; Lin, YG; Marcy, VR; Marino, MJ, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gruner, JA | 1 |
| Marcy, VR | 1 |
| Lin, YG | 1 |
| Bozyczko-Coyne, D | 1 |
| Marino, MJ | 1 |
| Gasior, M | 1 |
1 other study available for nomifensine and Disorders of Excessive Somnolence
| Article | Year |
|---|---|
The roles of dopamine transport inhibition and dopamine release facilitation in wake enhancement and rebound hypersomnolence induced by dopaminergic agents.
Topics: Amphetamines; Animals; Cell Culture Techniques; Disorders of Excessive Somnolence; Dopamine Plasma M | 2009 |